Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Adjusted indirect comparison using propensity score matching of osimertinib to doublet chemotherapy in patients with EGFRm T790M NSCLC who have progressed after EGFR-TKI

Date

08 Oct 2016

Session

Poster Display

Presenters

Frank Andersohn

Citation

Annals of Oncology (2016) 27 (6): 416-454. 10.1093/annonc/mdw383

Authors

F. Andersohn1, H. Mann2, T. Mitsudomi3, T.S.K. Mok4, J. Chih-Hsin Yang5, K. Papadakis6, C. Hoyle6

Author affiliations

  • 1 Frank Andersohn Consulting & Research Services, Berlin, Germany, Institute for Social Medicine , Epidemiology and Health Economics, Charite University Medicine, 10409 - Berlin/DE
  • 2 B&i, AstraZeneca, Cambridge/GB
  • 3 Department Of Surgery, Division Of Thoracic Surgery, Kinki University Faculty of Medicine, Osaka-Sayama/JP
  • 4 State Key Laboratory Of South China, Hong Kong Cancer Institute, Department Of Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, Sha Tin/HK
  • 5 Department Of Oncology And Department Of Medical Research, National Taiwan University Hospital, Taipei City/TW
  • 6 Global Payer Evidence And Pricing, AstraZeneca, Cambridge/GB
More

Resources

Background

In the absence of randomized data comparing osimertinib to platinum-based doublet chemotherapy (PBDC) in patients (pts) with metastatic epidermal growth factor receptor (EGFRm) T790M non-small cell lung cancer (NSCLC) who have progressed after EGFR-TKI, an adjusted indirect comparison can offer a robust estimate of treatment effect. The IMPRESS study placebo arm (PBDC) (data cut-off [DCO] 2014 May) included a subgroup of pts with the T790M mutation and disease progression following response to EGFR-TKI. Pts had similar demographic and disease characteristics as those in AURA extension (NCT01802632) and AURA2 (NCT02094261) trials of osimertinib (DCO May 2015), and therefore represent a valid comparator to demonstrate differences in outcomes.

Methods

The efficacy of osimertinib relative to PBDC was assessed using an adjusted indirect comparison of two non-randomized data sets comprising pts with a confirmed T790M mutation (by tissue or plasma ctDNA respectively): AURA (N = 405) and IMPRESS placebo arm (N = 60). A propensity score (PS) approach was used to adjust for differences in baseline demographics and disease characteristics. Baseline characteristics of both groups were compared using statistical tests. The PS model included 22 variables with P 

Results

Following estimation of PS for each pt and balancing across the groups (osimertinib N = 287, PBDC N = 51) osimertinib demonstrated: A statistically significant improvement in median progression-free survival (PFS) of 9.7 months vs 5.3 months (HR 0.28, 95% CI 0.19–0.42, P 

Conclusions

In this indirect comparison, a statistically significant improvement in PFS and ORR was demonstrated for osimertinib compared to PBDC. AURA3 will provide a randomized comparison of osimertinib and PBDC.

Clinical trial identification

Legal entity responsible for the study

AstraZeneca

Funding

AstraZeneca

Disclosure

F. Andersohn: Consultancy fees from AstraZeneca. H. Mann, C. Hoyle: AstraZeneca employee and stock in AstraZeneca. T. Mitsudomi: Membership on advisory boards for AstraZeneca, Chugai, Boehringer Ingelheim, Roche and Pfizer. Corporate-sponsored research for Boehringer Ingelheim, Chugai and Pfizer. No stock ownership or other substantive relationships. T.S.K. Mok: Advisory boards: AZ, Roche, Pfizer, EliLilly, BI, MerckSerono, MSD, Janssen, Clovis, Bio Marin, GSK, Novartis, SFJ, ACEA, Vertex, Aveo&Biodesix, BMS, geneDecode, OncoGenex. Grants: AZ, BI, Pfizer, Novartis, SFJ, Roche, MSD, Clovis, BMS. Stock: Sanomics. Other: PrimeOncology, Amgen, PeerVoice. J. Chih-Hsin Yang: Advisory boards: Boehringer Ingelheim, Eli Lilly, Bayer, Roche / Genentech / Chugai, AstraZeneca, Astellas, MSD, Merck Serono, Pfizer, Novartis, Clovis Oncology, Celgene, Innopharma&Merrimack. No stock ownership, research grants or other substantive relationships. K. Papadakis: Employee of AstraZeneca. No stock ownership or other substantive relationships.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings